Romania Attention Deficit Hyperactivity Disorder Therapeutic Market Analysis Report 2022 to 2030

Romania ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

Romania's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $86 Mn in 2022 to $156 Mn in 2030 with a CAGR of 7.75% for the year 2022-2030. The rising rate of ADHD in Romania and consequently the increasing demand for its therapeutic options are driving the growth of the market. The Romania ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Sun Wave Pharma, Oftafarma Romania, and Prude Pharma are some of the key players in the market.

ID: IN10ROPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: Romania AUTHOR: Parul Choudhary

Buy Now

Romania Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Romania Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $86 Mn in 2022 and is projected to reach $156 Mn in 2030, exhibiting a CAGR of 7.75% during the forecast period. The draft, which was made public by the Romanian finance minister earlier this week, projects that public investment spending will account for 7.22% of GDP, or $24 Bn, in 2023. At 1,696 euros per person, Romania had the lowest health expenditure. Due to the government's significant budget deficit, the Romanian government has stated spending on health care will be reduced by approximately $911.2 Mn.

According to the Analysis of mental health services for children in Romania research done by Salvati Copiii and CURS, about 200,000 children in Romania have attention deficit hyperactivity disorder or ADHD. Only 8,000 of the totals, or 4%, are identified in the records of experts and receive care. When compared to children without this behavioral disorder, most ADHD patients perform poorly in school. Less than 9.1% of children with ADHD complete college, compared to 98.7% of children without ADHD who successfully complete secondary school. Over 70% of students have been suspended or expelled from school, and 45.5% have cognitive disabilities. There are concerns that some of the vulnerable children being managed by the Romanian state may be receiving medication to control challenging behavior because vulnerable children are up to 15 times more likely than other Romanian children to be labeled with ADHD.

In Romania, therapy and medication are frequently used in the management of ADHD. The stimulants methylphenidate (Ritalin) and amphetamines (Adderall) are the ones that are most frequently given in Romania for ADHD. These drugs function by raising dopamine and norepinephrine levels in the brain, which can enhance concentration, attention, and impulse control. Additionally, non-stimulant drugs like atomoxetine (Strattera) may be used. In conjunction with drugs, behavioral counseling is frequently suggested to help people with ADHD develop new abilities and coping mechanisms for dealing with their symptoms. Cognitive-behavioral therapy (CBT), parent education, or social skills instruction are all possible forms of counseling.

romania attention deficit hyperactivity disorder therapeutics market analysis

Market Dynamics

Market Growth Drivers

Recent research indicates that the prevalence of ADHD has been steadily rising in Romania over time, which is anticipated to continue fueling the Romania ADHD therapeutics market's expansion. Additional funding is being allocated to the treatment of ADHD in Romania as healthcare expenditure rises. This is anticipated to drive the Romania ADHD therapeutics market's expansion.

Market Restraints

Patients' access to treatment for ADHD may be hampered by budgetary restrictions like scarce resources or financial challenges. This may restrict the Romania ADHD therapeutics market expansion. Some patients may not be able to receive treatment because of the costly nature of ADHD treatments and medications. Because of this, market size may decrease and development may be slower. ADHD may be stigmatized and misunderstood in Romania, which can result in improper evaluation and care. This may restrict the Romania ADHD therapeutics market expansion.

Competitive Landscape

Key Players

Torus Pharma (ROU)
Besmax Pharma (ROU)
Sprint Pharma (ROU)
Sun Wave Pharma (ROU)
Oftafarma Romania (ROU)
Prude Pharma
NEOS Therapeutics
Amneal Pharmaceuticals
Janssen Pharmaceuticals
Noven Pharmaceuticals
RespireRx Pharmaceuticals

Healthcare Policies and Regulatory Landscape

Romanian pharmaceuticals intended for human consumption are evaluated for safety by the National Agency of Medicines and Medical Devices (NAMMD). The NAMMD ensures that medical devices used by healthcare networks continue to operate at a high standard of performance and safety. Furthermore, the agency makes sure that patients and medical workers have access to pertinent information about drugs. In order to safeguard the public's health, NAMMD is in charge of gathering and analyzing data on the security of pharmaceuticals and medical devices marketed in Romania. NAMMD makes sure that drugs and medical equipment are produced in accordance with good manufacturing practices and satisfy quality standards. Healthcare workers and the general public can learn about medicines and medical devices, including how to use them properly and what risks and benefits they may have, due to NAMMD. It is crucial in guaranteeing the efficacy and safety of drugs and medical equipment in Romania and in advancing the population's health and well-being.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behaviour Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.